Fine Foods & Pharmaceuticals N.T.M Future Growth
Future criteria checks 4/6
Fine Foods & Pharmaceuticals N.T.M is forecast to grow earnings and revenue by 30.7% and 13.1% per annum respectively. EPS is expected to grow by 1.8% per annum. Return on equity is forecast to be 12.7% in 3 years.
Key information
30.7%
Earnings growth rate
1.8%
EPS growth rate
| Life Sciences earnings growth | 26.2% |
| Revenue growth rate | 13.1% |
| Future return on equity | 12.7% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 338 | 18 | 8 | 37 | 1 |
| 12/31/2025 | 281 | 13 | -21 | 30 | 1 |
| 12/31/2024 | 245 | 10 | -6 | 25 | 2 |
| 9/30/2024 | 243 | 5 | 12 | 42 | N/A |
| 6/30/2024 | 247 | 3 | 18 | 40 | N/A |
| 3/31/2024 | 252 | -4 | 9 | 28 | N/A |
| 12/31/2023 | 252 | -4 | 0 | 19 | N/A |
| 9/30/2023 | 240 | 1 | -7 | 10 | N/A |
| 6/30/2023 | 234 | -5 | -11 | 6 | N/A |
| 3/31/2023 | 222 | -4 | -7 | 10 | N/A |
| 12/31/2022 | 207 | -10 | -12 | 4 | N/A |
| 9/30/2022 | 203 | -10 | -18 | 2 | N/A |
| 6/30/2022 | 196 | -1 | -25 | -5 | N/A |
| 3/31/2022 | 194 | -6 | -25 | -7 | N/A |
| 12/31/2021 | 195 | -1 | -22 | -6 | N/A |
| 9/30/2021 | 198 | -1 | -6 | 7 | N/A |
| 6/30/2021 | 200 | 2 | 3 | 17 | N/A |
| 3/31/2021 | 190 | 13 | 4 | 18 | N/A |
| 12/31/2020 | 177 | 13 | 15 | 30 | N/A |
| 9/30/2020 | 162 | 8 | 2 | 19 | N/A |
| 6/30/2020 | 153 | -1 | 1 | 19 | N/A |
| 3/31/2020 | 157 | -2 | 0 | 19 | N/A |
| 12/31/2019 | 161 | -3 | -1 | 19 | N/A |
| 9/30/2019 | 157 | 8 | -6 | 17 | N/A |
| 6/30/2019 | 153 | 9 | -12 | 14 | N/A |
| 3/31/2019 | 147 | 9 | -52 | 6 | N/A |
| 12/31/2018 | 140 | 9 | -93 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9S5's forecast earnings growth (30.7% per year) is above the savings rate (1%).
Earnings vs Market: 9S5's earnings (30.7% per year) are forecast to grow faster than the German market (21% per year).
High Growth Earnings: 9S5's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 9S5's revenue (13.1% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 9S5's revenue (13.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9S5's Return on Equity is forecast to be low in 3 years time (12.7%).